Biological therapies in breast cancer: Common toxicities and management strategies

In recent years, a number of new molecules e commonly known as biological therapies e have been approved or are in late stages of regulatory evaluation for the treatment of advanced breast cancer. These innovative compounds have improved treatment efficacy and have probably contributed to the increase in survival length observed in some breast cancer subtypes. However, these agents are not deprived of toxicity, which can impair quality of life and may occasionally be life-threatening. In this article, we reviewed the most common toxicities associated with these drugs and provided a number of practical recommendations on their optimal clinical management.

Palavras-chave

Breast cancer, Trastuzumab, Pertuzumab, Lapatinib, Bevacizumab, Trastuzumab-emtansine, Everolimus

URI

https://observatorio.fm.usp.br/handle/OPI/4023

Referências

[Anonymous], 2013, STUDY PERTUZUMAB ADD
Armstrong TS, 2012, NEURO-ONCOLOGY, V14, P1203, DOI 10.1093/neuonc/nor223
Au HJ, 2013, ONCOLOGIST, V18, P812, DOI 10.1634/theoncologist.2013-0091
Awada A, 2008, EUR J CANCER, V44, P84, DOI 10.1016/j.ejca.2007.10.003
Baselga J, 2012, NEW ENGL J MED, V366, P520, DOI 10.1056/NEJMoa1109653
Baselga J, 2009, J CLIN ONCOL, V27, P2630, DOI 10.1200/JCO.2008.18.8391
Baselga J, 2012, NEW ENGL J MED, V366, P109, DOI 10.1056/NEJMoa1113216
Bowles EJA, 2012, J NATL CANCER I, V104, P1293, DOI 10.1093/jnci/djs317
Burris HA, 2004, ONCOLOGIST, V9, P10, DOI 10.1634/theoncologist.9-suppl_3-10
Cardinale D, 2010, J CLIN ONCOL, V28, P3910, DOI 10.1200/JCO.2009.27.3615
Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2
Choueiri TK, 2011, J CLIN ONCOL, V29, P632, DOI 10.1200/JCO.2010.31.9129
Costa RB, 2010, ANN ONCOL, V21, P2153, DOI 10.1093/annonc/mdq096
Criscitiello C, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3142
Dahabreh IJ, 2008, ONCOLOGIST, V13, P620, DOI 10.1634/theoncologist.2008-0001
de Azambuja E, 2009, TARGET ONCOL, V4, P77, DOI 10.1007/s11523-009-0112-2
de Oliveira MA, 2011, ORAL ONCOL, V47, P998, DOI 10.1016/j.oraloncology.2011.08.009
Eisen T, 2012, JNCI-J NATL CANCER I, V104, P93, DOI 10.1093/jnci/djr511
Ellard SL, 2009, J CLIN ONCOL, V27, P4536, DOI 10.1200/JCO.2008.21.3033
Eschenhagen T, 2011, EUR J HEART FAIL, V13, P1, DOI 10.1093/eurjhf/hfq213
Ewer MS, 2005, J CLIN ONCOL, V23, P7820, DOI 10.1200/JCO.2005.13.300
Fonseca LG, 2012, ANN ONCOL, V23, P455
Franklin MC, 2004, CANCER CELL, V5, P317, DOI 10.1016/S1535-6108(04)00083-2
Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320
Gianni L, 2012, LANCET ONCOL, V13, P25, DOI 10.1016/S1470-2045(11)70336-9
Guarneri V, 2006, J CLIN ONCOL, V24, P4107, DOI 10.1200/JCO.2005-04.9551
Izzedine H, 2009, ANN ONCOL, V20, P807, DOI 10.1093/annonc/mdn713
Izzedine H, 2010, EUR J CANCER, V46, P439, DOI 10.1016/j.ejca.2009.11.001
Joensuu H, 2006, NEW ENGL J MED, V354, P809, DOI 10.1056/NEJMoa053028
Lacouture ME, 2006, NAT REV CANCER, V6, P803, DOI 10.1038/nrc1970
Mahe E, 2005, TRANSPLANTATION, V79, P476, DOI 10.1097/01.TP.0000151630.25127.3A
Mahe E, 2006, J AM ACAD DERMATOL, V55, P139, DOI 10.1016/j.jaad.2005.11.1072
Maitland ML, 2010, J NATL CANCER I, V102, P596, DOI 10.1093/jnci/djq091
Marras LC, 2000, CANCER, V89, P640, DOI 10.1002/1097-0142(20000801)89:3<640::AID-CNCR20>3.0.CO;2-E
Miles DW, 2010, J CLIN ONCOL, V28, P3239, DOI 10.1200/JCO.2008.21.6457
Miller K, 2007, NEW ENGL J MED, V357, P2666, DOI 10.1056/NEJMoa072113
Momin SB, 2010, J DRUGS DERMATOL, V9, P627
Montero AJ, 2012, NEW ENGL J MED, V366, P374, DOI 10.1056/NEJMe1113368
Motzer RJ, 2010, CANCER-AM CANCER SOC, V116, P4256, DOI 10.1002/cncr.25219
Mourad JJ, 2008, ANN ONCOL, V19, P927, DOI 10.1093/annonc/mdm550
Moy B, 2007, ONCOLOGIST, V12, P756, DOI 10.1634/theoncologist.12-7-756
Nalluri SR, 2008, JAMA-J AM MED ASSOC, V300, P2277, DOI 10.1001/jama.2008.656
Niraula S, 2012, J CLIN ONCOL, V30, P3012, DOI 10.1200/JCO.2011.40.3824
Perez EA, 2004, J CLIN ONCOL, V22, P322, DOI 10.1200/JCO.2004.01.120
Perez-Soler R, 2005, J CLIN ONCOL, V23, P5235, DOI 10.1200/JCO.2005.00.6916
Phillips GDL, 2008, CANCER RES, V68, P9280, DOI 10.1158/0008-5472.CAN-08-1776
Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306
Plewig G, 1998, DERMATOLOGY, V196, P102, DOI 10.1159/000017841
Populo H, 2012, INT J MOL SCI, V13, P1886, DOI 10.3390/ijms13021886
Porta C, 2011, EUR J CANCER, V47, P1287, DOI 10.1016/j.ejca.2011.02.014
Procter M, 2010, J CLIN ONCOL, V28, P3422, DOI 10.1200/JCO.2009.26.0463
Ranpura V, 2010, AM J HYPERTENS, V23, P460, DOI 10.1038/ajh.2010.25
Robert NJ, 2011, J CLIN ONCOL, V29, P1252, DOI 10.1200/JCO.2010.28.0982
Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122
Romond EH, 2012, J CLIN ONCOL, V30, P3792, DOI 10.1200/JCO.2011.40.0010
Schneeweiss A, 2011, CANC RES, V71
Serrano C, 2012, ANN ONCOL, V23, P897, DOI 10.1093/annonc/mdr348
Shord SS, 2009, AM J HEALTH-SYST PH, V66, P999, DOI 10.2146/ajhp080455
Slamon D, 2011, NEW ENGL J MED, V365, P1273, DOI 10.1056/NEJMoa0910383
Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101
SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106
Soefje SA, 2011, TARGET ONCOL, V6, P125, DOI 10.1007/s11523-011-0174-9
Tocchetti CG, 2012, EUR J HEART FAIL, V14, P130, DOI 10.1093/eurjhf/hfr165
Verma S, 2012, NEW ENGL J MED, V367, P1783, DOI 10.1056/NEJMoa1209124
Viani GA, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-153
White DA, 2010, AM J RESP CRIT CARE, V182, P396, DOI 10.1164/rccm.200911-1720OC
Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016
Zhou XL, 2009, BREAST CANCER RES TR, V117, P577, DOI 10.1007/s10549-009-0310-8
Zhu XL, 2007, AM J KIDNEY DIS, V49, P186, DOI 10.1053/j.ajkd.2006.11.039

Coleções

Artigos e Materiais de Revistas Científicas - FM/MDR
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/InRad
Artigos e Materiais de Revistas Científicas - LIM/24
Artigos e Materiais de Revistas Científicas - ODS/03

Página do item completo